Volastra Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Volastra Therapeutics, Inc. - overview
Established
2019
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2019, Volastra Therapeutics, Inc. is a biotechnology company that provides treatment for metastatic cancers. The company was founded by Lewis Cantley, Olivier Elemento, and Samuel Bakhoum, and in March 2023, Volastra Therapeutics, Inc. raised USD 60 million in series A funding co-led by ARCH Venture Partners, Polaris Partners, and Eli Lilly & Company, with participation from Catalio Capital Management, DROIA Ventures, and Vida Ventures.
As of 2023, the firm is led by its CEO Charles Hugh-Jones. Volastra Therapeutics, Inc. develops chromosomal instability (CIN)- targeted novel therapeutics that include KIF18A inhibitor, VLS-1488. The company intends to use the March 2023 funding for the clinical development of its KIF18A inhibitor drug portfolio and the advancement of its drug research pipeline for treating chromosomally unstable cancers.
Current Investors
ARCH Venture Partners, Polaris Partners, Droia Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.volastratx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.